Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,226 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,226 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04032704 | A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | Phase 2 | terminated | Jul 25, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05576077 | A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors(STARLING) | Phase 1 | terminated | Oct 12, 2022 | Turnstone Biologics, Corp. | Sponsor decision | Sponsor / business decision |
| NCT03812289 | Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer | N/A | terminated | Jan 23, 2019 | OHSU Knight Cancer Institute | PI decision | Other (stated, no rule matched) |
| NCT00881621 | Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer | Phase 2 | terminated | Apr 15, 2009 | Georgetown University | slow enrollment | Enrollment / accrual |
| NCT06848556 | Evaluate the Effect of Tirazamine on Primary Liver Cancer. | Phase 1 / Phase 2 | terminated | Feb 27, 2025 | Zhejiang Raygene Pharmaceuticals Co., Ltd | Company Operational Strategy Adjustment | Sponsor / business decision |
| NCT04268888 | Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC(TACE-3) | Phase 2 / Phase 3 | suspended | Feb 13, 2020 | The Clatterbridge Cancer Centre NHS Foundation Trust | Analysis meant the study should close to recruitment | Enrollment / accrual |
| NCT04406857 | Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy… | Phase 1 | terminated | May 29, 2020 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced… | Phase 3 | terminated | Jan 14, 2021 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | IDMC recommended to terminate the study since Interim analysis showed that the experimental group… | Efficacy / futility |
| NCT03169777 | QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects… | Phase 1 / Phase 2 | withdrawn | May 30, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT03563144 | QUILT-3.088: NANT Pancreatic Cancer Vaccine | Phase 2 | withdrawn | Jun 20, 2018 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04804696 | Toripalimab with Paclitaxel and Cisplatin As Neoadjuvant Treatment for Esophageal… | Phase 2 | terminated | Mar 18, 2021 | Peking University | Several clinical trials had showed that anti-PD-1 agents combined with chemotherapy as neoadjuvant… | Other (stated, no rule matched) |
| NCT04863430 | Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the… | Phase 2 | withdrawn | Apr 28, 2021 | Peking University | The anti-PD-1 agents were proved effective by several clinical trials and recommended to treat… | Other (stated, no rule matched) |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT05523154 | "Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile… | N/A | terminated | Aug 31, 2022 | Mayo Clinic | lack of funding | Funding |
| NCT05909995 | Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid… | Phase 1 | terminated | Jun 18, 2023 | Incyte Corporation | This was a strategic business decision. There were no safety concerns contributing to this decision. | Safety / toxicity |
| NCT03822936 | Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas…(PIOPPO) | Phase 2 | terminated | Jan 30, 2019 | CNAO National Center of Oncological Hadrontherapy | The study was early closed due to low accrual in August 2022. | Enrollment / accrual |
| NCT05191667 | AN0025 and Chemoradiotherapy Combination in Esophageal Cancer | Phase 1 | suspended | Jan 13, 2022 | Adlai Nortye Biopharma Co., Ltd. | The study is not stopped but the enrollment is suspended until a further decision from sponsor. | Enrollment / accrual |
| NCT00961571 | Sunitinib and Capecitabine for First Line Colon Cancer | Phase 2 | terminated | Aug 19, 2009 | Georgetown University | Unanticipated side effects and futility | Efficacy / futility |
| NCT01205828 | ABT-888 and Temozolomide for Liver Cancer | Phase 2 | terminated | Sep 21, 2010 | Georgetown University | Lack of efficacy | Efficacy / futility |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05229900 | A Study of SGN-ALPV in Advanced Solid Tumors | Phase 1 | terminated | Feb 8, 2022 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | Phase 1 | terminated | Dec 14, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05296005 | Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers | Phase 1 | withdrawn | Mar 25, 2022 | Ohio State University Comprehensive Cancer Center | PI Decision | Other (stated, no rule matched) |
| NCT05631574 | Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small… | Phase 1 | terminated | Nov 30, 2022 | Biomea Fusion Inc. | Biomea Fusion, Inc., is no longer pursuing oncology indications for BMF-219. No safety concerns or… | Safety / toxicity |
| NCT02935478 | Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver… | N/A | suspended | Oct 17, 2016 | St. Louis University | IRB reviewing study conduct and adverse events | Safety / toxicity |
| NCT05158374 | Molecular Effects of Aspirin & Metformin on Colonic Epithelium | N/A | withdrawn | Dec 15, 2021 | University of Edinburgh | withdrawn prior to gaining approvals | Other (stated, no rule matched) |
| NCT06702384 | Molecular Analysis of Gastric and OEsophageal Cancers STudy(MAGnET) | — | withdrawn | Nov 25, 2024 | Royal Marsden NHS Foundation Trust | Never opened to recruitment due to lack of funding | Enrollment / accrual |
| NCT02853500 | Effect of Surefire Infusion Device on Tumor Response to Regional Intra-arterial Therapy… | Phase 4 | withdrawn | Aug 3, 2016 | Dana-Farber Cancer Institute | No participants enrolled. Inability to perform intraprocedural MRI with the intraarterial infusion… | Enrollment / accrual |
| NCT03117972 | Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and…(CLavSyn) | Phase 2 | terminated | Apr 18, 2017 | Centre Hospitalier Universitaire de Besancon | enrollment too slow | Enrollment / accrual |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and…(MYCHELANGELO I) | Phase 1 / Phase 2 | terminated | Aug 11, 2022 | Omega Therapeutics | Sponsor decision to terminate after monotherapy dose escalation. | Sponsor / business decision |
| NCT03764137 | Imaging with [89Zr]Panitumumab-PET/MRI in Patients with Newly Diagnosed Colorectal Cancer(Panitumumab) | Phase 1 / Phase 2 | withdrawn | Dec 4, 2018 | University of Alabama at Birmingham | Study was not able to enroll any subjects | Enrollment / accrual |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory… | Phase 2 | terminated | Nov 9, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT05845502 | Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced… | N/A | terminated | May 6, 2023 | Shantou University Medical College | Failed to recruit more volunteers | Enrollment / accrual |
| NCT02672917 | Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen… | Phase 1 | terminated | Feb 3, 2016 | BioNTech Research & Development, Inc. | Sponsor decision | Sponsor / business decision |
| NCT04916236 | Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers(SHERPA) | Phase 1 | terminated | Jun 7, 2021 | The Netherlands Cancer Institute | Due to a lack of safety and efficacy. | Safety / toxicity |
| NCT06341647 | Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 | Phase 1 | withdrawn | Apr 2, 2024 | GC Cell Corporation | Determined that enrollment would be limited due to the change in care setting. | Enrollment / accrual |
| NCT02485834 | FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced… | Phase 2 | terminated | Jun 30, 2015 | Alliance for Clinical Trials in Oncology | Poor accrual | Enrollment / accrual |
| NCT06206876 | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | withdrawn | Jan 16, 2024 | Roswell Park Cancer Institute | never opened | Other (stated, no rule matched) |
| NCT05776875 | Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC | Phase 2 | terminated | Mar 20, 2023 | Yale University | Low enrollment | Enrollment / accrual |
| NCT04066660 | Study of Oligo-Fucoidan in Advanced Hepatocellular Carcinoma (HCC) | N/A | terminated | Aug 26, 2019 | Hi-Q Marine Biotech International, Ltd. | After interim analysis, we planned to recruit 100 participants. However, due to COVID-19… | COVID-19 / pandemic |
| NCT05653427 | A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced… | Phase 2 | terminated | Dec 16, 2022 | Janssen Research & Development, LLC | N\~15 subjects data analysis did not meet statistical consideration of ORR and study… | Efficacy / futility |
| NCT04162665 | Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer | Phase 2 | terminated | Nov 14, 2019 | Washington University School of Medicine | Poor accrual and funding sponsor declared bankruptcy. | Enrollment / accrual |
| NCT02671890 | Disulfiram and Chemotherapy in Treating Patients With Refractory Solid Tumors or… | Phase 1 | terminated | Feb 2, 2016 | Mayo Clinic | lack of funding | Funding |
| NCT04807972 | Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV)… | Phase 1 | terminated | Mar 19, 2021 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT05717400 | Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma… | Phase 4 | terminated | Feb 8, 2023 | M.D. Anderson Cancer Center | PI Request | Other (stated, no rule matched) |
| NCT01167725 | Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With… | Phase 3 | terminated | Jul 22, 2010 | Alliance for Clinical Trials in Oncology | not stated | Not stated |
| NCT05861336 | GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally…(OVERPASS) | Phase 2 | withdrawn | May 16, 2023 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | No patients enrolled | Enrollment / accrual |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT05281276 | Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC) | Phase 1 | terminated | Mar 16, 2022 | Taipei Medical University Shuang Ho Hospital | The overall profile does not support development for metastatic colorectal cancer | Other (stated, no rule matched) |
| NCT04214418 | Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint…(MEKiAUTO) | Phase 1 / Phase 2 | terminated | Jan 2, 2020 | Columbia University | Toxicity and Lack of Efficacy | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 10, 2025source: clinicaltrials